iJ`ssjeJiim`asugimiJU`snanunga jjna illii`TiMsi^yis, n.u* miiHEJi

iJ`ssjeJiim`asugimiJU`snanunga jjna illii`TiMsi^yis, n.u* miiHEJi

iJ'ssjeJiim'asugimiJU'snanunga
jjna illii'TiMsi^yis, n.u*
miiHEJiflQunniyiiJvi'jiiQiifuniiiJvimuQ'iia^a^i'UQU11 i i a ^ itas^Pivin Focus group 5 flf-^
riiJiJf=iannivin-^nn-ai,mviEj
imiu
12 m
fiflflnsjanrn'slilmiJ'ssia^pi^inm'aHun
maniviuflismuiJiJJiTPi'iAi-lajJUiJijrlaiJjfini
i.iasiJiSsn'U^Tunuvi'UTEJ'^'TUpin^^ Iviiljwiaa-
mu^ai'uwefvini.fia'u iiiiJiijjmjfinnniiiJisiijjLLas'3'aLauauu:;ija^wt!iuii^ni^^
am^piama-^-asviQn^ai.fia'mininHii
wa
2551 - mim
2553 2) ilisLCi'ui.iJIuumEJUisuufn'a
ciTuvi 1 nninajuni:;iJijnnite1nisT'-^ainniljJvi<^iJisa^fl^innniH^ i i a ^
civiQ'ai^'iN'W'iI'MLfiiFi'asiJU ^^iJisinauflQ!] ismDUilgiJli flow chart ituuvla'ful'Ufn'amjvin
mifiPii?ii3J itasmiiiEJ^TUwa
nninpuuiRQniiiLtatfTnti'sI'urinii.fl'iirT'-^ annTslaiw
iiv.Y[ 2 nniiJistduisiJijnnii,flnit'>aainniliin-^iJisa^R^nnnniHu'i mmv.
m\>^u imeiz
0.2 , 0.8 uas 0.5 pnuaiflii aasvia'-^fn-STAiiai'UTiAiu'i'i
ifwdn^a
nnimfufnifnH'n
ma-^^nnnmi.nfl anm-aliin-^iJ'aSGi^fl^nnmiiHEjn aasmimfl'Si dapinafliiaua^m'iriatj
nninaj'U'T5:;uDa£)'n^¥fli.^'u inaj^^Fmniuuii^aua^mimfl ainiiljimilisei-^FisnnniiHijn
Xmzm
5 uai;.6 i i m n
mn
7 ?\i^ nauminaj'un miifui.fl'u 13flf'^uasapia^tvila
4 Fif^ I'uisvi'ii^ati.asvia-^minRJui uaslii'Muain'iiIiiwiJiSsi^fl^nnnniHEjn luispiij 6 tau
muviSKnnimj'uniisiJiJ uaQ
afi) nninput4nisiJijnnitp1iisT'^annnililmiJi:;6^^fl'^innniH^
^Hfliij 3 flTU \mn
niie\iiiimmimzm\K'Biiiii
^•uaunuils^'EJ
fiu^an'ufii.'iiiio^ ii,a:;mifl6iQui'3JJua^
aviinn^vi vinlwmflisiJijmviiiniiGiiiniieimiT'Uii'Bi'Ufja ci^waMnmiEJ-^Tunnimi?! anmi
liiwiJisa-^n^ifim-sHun
tvijj^^^u niajj'iT^nnimnnMi^nunijnai.ua^a^nnanniiljJw
lilt65^3R^inm-jHui Ltasmiififl anmiliifJ'^ilita^afl^infniHEJ'i ImsfliJi'ui.Li^afltlaEja^
Fin^nFifu : nnitfliisT'^annniliimiJ'aSei^api unfnwnliR^fl
* fisniTun'ii'runa
Qn?s^nfI?-3ntjnLna^?finjnjn ilw 11 niJii^ 1 jjn?n?i3J 2554
Adverse drug
reaction
surveillance
institute's
: Rajanukul
experience
Malee Prechapotsit, B.Sc. (Pharmacy)*
Abstract
Objective To
develop and
evaluate adverse drug reactions
(ADR)
surveillance of high alert and antipsychotic drugs at Rajanukul Institute.
Materials and
was
methods : This study was
divided into 2 steps. The first
to develop adverse drug reactions (ADR)
surveillance that started from
literature reviews on ADR
surveillance and found 11 related articles. And
rounds of focus groups, an
establish this system. So we
then 5
average 12 health professionals, were used to
got a pilot project, work procedure and coordinate
with ward staffs to follow and
collect ADR
data. The
data collecting and
synthesis for continuous quality improvement had conducted from January 2008
-March 2010. The
number of ADR
second step was
reports, ADR
to evaluate this system by comparing the
related admission, recurrent ADR
& its severity
before, during & after development.
Results In the first step, the development of this ADR
depended on
surveillance
was
three major factors including; pohcy support, team work, &
stakeholders participation. Its system contained standard procedures, flow charts,
record forms, training, mentoring, monitoring, supports, etc. The
there were 0.2, 0.8
&
0.5
percent of ADR
second step,
reports before, during &
development, respectively. After implementing this system, the rate of
related admission & recurrent ADR
of ADR
were less than before. And
after
ADR
also, the severity
on 5th & 6th levels before development were 7 cases, then increased
to 13 cases during development, and reduce to 4 cases after implementation.
Conclusions The major factors; policy support, team work, & stakeholders
participation are important to the development of ADR
benefit the institutions including greater ADR
admission, recurrent ADR
surveillance that will
reports, less ADR
& its severity.
Key words : adverse drug reaction surveillance, antipsychotic drugs
* Rajanukul Institute
Journal of Srithanya Hospital
42
related
1 u aiiJ-3 n Ei ^ Tu a n m l l JJ w ^a LJ-s i; a ^ f=i
MWUI
^ i n m i H u i 111^:^13 2550 Da^Fjuutfln
1-T^a Fl Q n il LI a aflffufln u w aflfl tu a u/I n n
LQnnsyii^i^nnifluafny'ii.i.asiJin'i'SimwS
miiii
inn ail central nervous system
tfl u n a ij u n vj s5 ^a
iMmjwiliEJuan m i i l u i t i m z
28.1
11 n H tnfla 1 m i l i j n
uaj; iliSffi^afllfl^^Lflu auflii 3 la^^nnunnaij
general infective system ki,as;unnaiJ
25.5 pnuaiflii^ SnuHunneiiiuu'inndn
musculo-skeletal system^
iaueis 50 flQaun^ija-amn'U'S'ni.iasiuifnwn
IlR^fl tiJu carbamazepine, lamotrigine,
li^anininavianEJUvi^alflvrajunisiiiu
phenobarbital, phenytoin , sodium
nnitSnx'^amii.nflannn'aliJwLl'atG^^afl'mn
valproate uas clozapine tiluflu STU^fl
nniHun^'^ vi'faiivi^iJ'3:;tfj'uiJ'5S^viBwa
i,fluuififlf=nnjj Ju^a-a (high alert drug,
iia^isuuni'ji.KnisQ-^nnii.nflanmiliim
HAD)
iJii;a^fl'^nnnniil'Bynvinaj'U'i^'utviiJi,i,aslfl
^^utnintfliJQ-^l'unn'sfnHi
(therapeutic index) Uflu^'^ aas^flanmii
fuflQiijiQiiSa^nnavianinQ'anfvi
iinH
sninnnfluviuannnililn-aiJisa^afl'^nnnn-a
anniiunuiituu
Steven
Hunlfli.viiif'u
Johnson
uasiiiQuafllannaviwiJQUi.nfl
syndrome , extrapyramidal symptoms
(EPS) , agranulocytosis .
ua^a
a un^al-anflnijli-^n unun a vflflVN'ajtn
a>aflnniaijnd'uTanMMm^infl(=iQ'i3J
isuumiL^n'aST'-aanniiljJwiJisia-^fl'^nn
anm'aljJn^iJ'jSiei^fl^nnnniHiJi
nniHun f^TuIviiiji.Lluli^viEjnLna'MQliJ
(adverse drug reactions, ADR) 111,1114
LJitnaunij lnii
iJ2niunfimflf"uIfluCllflfl4^ upitfluaupi
iTBiunalflfinvi'Uflaflinmiflflflniiannni
nfjpiaii'UM'!! LLSiiLnflf'utiial'BEjnl'uu'unfl
s
liiwLliSci^fl'^nnm'aHinflTiii t^u^^^ itas
linHmamifla^rru i u ^ q u
mimi
n.fl. 2548
amilu
u n fn »nT 1fl^ fl "uflQ I'llflvi u ^ ij a >a a fl n iJiJ
Vila
iniiTuna naiJ^TUt^^nmujlfliQiJilanii
fnanTifl Vila maLLiau'uuiJa^aunliimi
m^i'nii'hi^mimiiti<i
vii-^TUua^aQUQsIuin^fnu^
LvJanaiuTssuu
nnii,e^ni5;Tr'^annniliifI-^iJ"3S6^<^fl'^nnn'i'5H
isfliJFiQnjJi'Ui.i.i^aija^i.viflnniirlljim
unua^aafniTt! tii'uvid^'unn'a'waj'un^TU
liisef^fl^nnmiiHEjn ^^iJiij;uni^'^'innnt
s
t^aiiniiiiHiiijnfli^nu
i.i.atiJiti.d'u
i.m'^flQijj'auai^ija^aLilin'iidflnijn'iiaiJ^a
iJii:;lviswa'jja^'3j;uufl^na'm
iJ'3tmvif=ni3JFiaiPimia'uvn^ui^'^ Ifltflu
11 a il al u n n 1 VTPU TJ n fl /I n VI ^ n u Ll 1 n n i H fl
9 isfliipnu NCCMERP TflUfl^i,tpi'5j;i?iu
t^^ii
liQijaflafl'aimiii.fiflannniiliiff^
A-I f^ailisEjnfltLim^PiiJ 1- 9
Qn?2in?t?>3ViinijnaHtfinjfijn t l ^ 11 'aiTu^ 1 3jn?nf=i3J 2554
43
tvlaHtLl'u
ifluisuu
izm?\iimM\ii<i
^'un'asmfi^mii.fllujjfli'ijj
^Al1au^,viafufn1fln^•3lJ1a^aflfu/nvl
uasmimflanmiiliiw
li-^Vfununa (HA) \m\2 ^-^Iflt^jj
miHaififiua^awilQSJi.fl'Ui.il'ivijjnua^acifl
fliiuumiaun^atfluisuij
IfluSnajj^aTU
i,/i^'2n'5iijji,fli4imuij'iti!fltui;niiiufn'3ituum
^^drnjAau^nmy 2 i s P N U
1.1. m'aviuvntjmfuniiaji'ui.flau
ifi a VI u n ll. a s LI 1 s I. Ji u w a 1 s; D u m 1
iflniin-^ann'iiliin^iJisgi^afl^nnn'iilM'i
nu/inmis 2552 m£jQrmiituunnii,^nisTi^
Fmjj i^u^a^ i.i,a:;uifnH'nIif=i^fl'l'uafiniT'u
anniiljiwiJisiei^afl'^'infniiHu'i
WJUVIATUJ
mnuTii'a^^TUTU l l rfa^
1.2. m'a^fl'Mi Focus group nuwJl
eiiui.nuTiia'a Ifluri i.i.vivi?l -wsjiLna
m-3 PIn 1*1 R f ^ Clflflnl u u m 1
isvi-ii^atl 2551 fi-^ 2553
iiJIiiui.yiuui.Li'u 3
{amim
lmmme}m
iziizPimnwn^xii
2551 - uniiflii 2552)
izv\ii-^
"nrnxii
(njj/nnufi 2552 -
nuhiiiu
2552)
aatvia^vTajuiituunn'3i,flT3tT''^
•umimMmnm
iiuiu
12 m
"Ml Focus group ri^ivw^
Tflu^fl
5fll'^l u
Llisi.fl'uilnjvinrin'smflann'TaljJwiJiita^afl'
^nnm'aHunua^elfniJ'U isi.iiEJUijgiJ'fl
flow chart iLuii'Waisjl'Ufn'airuvin
mi
flflflijj uasmiinu^'TUWe) flmufla-^mi
a'lmil.sJmiJ'asjci^fl'^nnnniHfj'i (flaiflu
lunnimjuiflinjJiuasmy^unnii.Hiis'M
2552 - V l i i m
anmilsJwiJisa^fl'^nnmiHEn
2553) ^•^fllSiLntlfni
iflaumitmEn
mjunil 2 mjfla'u fia
1. fn"3vraj'UT5:;uunT3i,plT3tT'^
isuumi
iJgniunitviQn^n'u
fliTEJi^a uasl^aa'uua'U'Ufli^^
lumi
aifniljJwiJisc^^H'^nnnniiHunflmit^u^
flim'umii.Snitl'^ anmiliJwiJiSe^^fl'^nn
^^uasunfni^il'afl^fl
miHunfln^l MaN^inlMDunu ismuu
2. fn'5iJis;i.fj'Ui5;uufn'3i,f1'ii:;n
anmiljJwiJitei-^fl'^nnniiHunviwuijnTO
ilgiJli flow chart a u u v l a i u l u m i M n
miflflflnu uasminu^aTuwa
Qsnniun iflla-^S a a^alill'Sl'uvi'UT L
1. m i ' i ^ a j u i i i t u D n i i i . p l i i i s f ^
aimiliJwiJ'Ssa^jR'sinnmiHu'i
Cimiiflni.u'u^aTUfl-^uflil 2551 iifl
^iM
l^itAuizviii^imuvMimmimM
muim
2552 f l m i l a a n i ismuuiJaiJfl
I,flu m 1fl°n 1, u u ^ n u el Ta T ^ a n m l l jj n-a
tmuiJis; idiJEJi ATI JJ
Llissi^fl'^nnm'al'Bui
a 1 m 1 •ui-31flu ^ n n n n i H £j 1 fn i*nT 1fl^ fl
Iflurieiaj-anii
m^nniiaj tiasiENljJlflJInn-anw'unaun^
aa t m i f lflflnii
lijfiiJ'at'B3Ji)a^vijJiJ'5S6^n'U'3s;fliJV]'U'3U^3n'u
Journal of Srithanya Hospital
44
t !J u iifln jj vi tJ T u ^ n u k u-3 s u 5; (, fl a vifl6^ a u
f=mjjflaifli.Fiaa'Uvn-^un
aimiiliif!^
fl-njjt'unl^
i,i,65:;I'WflTnjjiflnumii,fifl
iJ-5 s a >a Fl ^ n n n 1 i H u 1 n u •SI n u a u n fn w n
f\iivmi^\.mmY\i^t}i
TiFi^fl Fmjj|rfa^aun aripiprazole ttatui
isviQn-^ui
fnwnliFi^piQni.a'u
fluviniJtuviilunniilgijflflniJisimuiiilgijfl
'iii^3i,fla'unin/)nFi3J 2552 nsju^anu
i./i^iiniiiii^flinni,mijmji,WLii,miFiQnjJii,ia>a
anmi'iii^tFiu^a
snnLnviSFnnjji.^u>aa>a nn-simun
mizvu
?j 1 i T 3J n u vi jj iJ 11; 65 Tu 1 f l u M tJ T !j ^ n u
iJfui)i^i:;i.2uiiiJ2Lii
niasj^Fi'nni.fl'u
flow chart iiatilfuili^auijuvlaijjm'a
nu^nijFmjjFisnPH.Fiaa'uyn-aun mimpi
iJgnlunsviQi^aun a'ifniljJv?>aiJiisa^Fi^nn
nniHun i.viaaspiQfil'Ufni'snL^anuvin ifiau
ainniliJwilisa^fl'^nnmiHijn
tn a H f j n 1 111 2 iTIi a u n ^fla tu a ^ a a s
653JH,G5JJa
u
•wanmiiHin nnin-uun
mimflilgnlun
tflauflmflU 2552 - duiflil 2553
kfl'uiJi^via^'iAiPiJUTSSiiu
Jimivfi
uii u 65 a u fin 3JflQ n 3J m VI at^ u a w ll 2 iTfllu
miiilgijflflnjjiti.iluijil^ijfl uasLviyflQu'^
^''an
2 'S'a Fia aflnm'amflaifn'aljjn-^
ilisa^aA'Anuiutti-^irflu
6 fulil'Sni.fl'u
FjUEj ttasiaflnfn'smflainniljjwil'ssa-^fl'
^'innniiHuni.ua^^nnfl'En^nivi'UflHi.fli
<u
x-y-^aruflinlunisviQ'i^SEJ'i tflu 0
iJgiJliSciQ'u-siJjI'umiaani.muisuu Y\iiv
2. miiliisi.iiii'atuiinnitSTaJj'T^a
annniilwn-^il'a^a^fl'^irinniiHunninjj Jij-^
tflau^^vnFijj
2552 -
m a i m
2552 ilfiJiJ'a-^-asi.LiuiJiJgiJli'iia^nni'unm
a-auasuifriH'nLiifl^fl
t'unniilisi,Ji'uilij;iyisw65'jja^isiiii
iii^nnatinurtuniinaa'uviflFJunfipia-^tlln
1flEj t iJ 1 £1 u t vi u u'Ll a 3y 65 m-5 n £1 ^ 1-u n n It fi fl
iit'>aa'Ufl'5n1un'3svn'n>aun ttaz\.\iimuiJa^
annniiljJwiJisa^afl'^nnnniiHu'i
1 s 1.3 u 11 ll 2 LTA m 1
mim
^ n u u 1 Fl a
^ 1 u u 1 fnanMi^viuniina kua^^nn mflann-iilsJw
ili5;^TljiFnn,ni! 3 tfiat! ma^^nnila-^mj
ilnsa-afl'^inm-al'BEjn nTsmflaimiiljJn^a
iliijvnmt^ajjfltu/i'i'w
uan^nnuilNl.PiPini.lj'Ufinii.f'^ini.i.iiii
Intensive ADR
monitoring \<^iii'Ui
imt'a^'La^mimflanfn-aljJn-^ilii a-afl'^m
nn-aHunlu'iJQ^ariai!
ISVIQI-^
uasvia^
vf aj u 11 s u u m 11, H1-51 i^a a 1 n m l ji n ^3
m n H u 1 Fn 1 jj I. ^ u >a ^ ^3 a a t Ej n fn M-i11 Fl ^ flilii:;65^
^:;Snniufll'Mfl'3ijj|fln'U!j'ifl'3'ijji^u>aa-auaj;
uifnwnLifl^fli.mwiJnflia^^
fl'^inmiHun
flQiii
fni^iTifl^fl
uasSmifliT^
Tii'«^i?Iwv<£jniina^?finjfyi i l ^ 11 •amj^ 1 3jn?nhw 2554
" " 45
3^3 ua tfji
'snum'aunyifla^iflnis'T^annniliin^
iJisa^fl^nnnniHuniiijf^ nniawun UHR
i.^Ej-^65^aatuifn!*nT"5fl^fl
l^uniimmu
!j nlflu L Q vn s u 1 n u "a n fi d li Q 4 u n n 1 fn HI
afluaatunfnu-nl'afl^flfiiianm'jljjn-^
annnild'M'aiJiSei-^fl^nnnniHun'iia-^anniT'u
iliiSsi^fl'vi'a'uai^ ei^wan-s^yiu-a'ua'j^ vifajj
fl'nvin'sndtfla'sfianflfiJi.via^'sa^'aaiJ
1. izfiiiiUmiii
nnviuflflunvifla^ i,clT35;->^ai!fl'3nl!jn
Imumimue^uu
isiVi-in^un (drug-drug interaction, Dl)
iiiiiv.
2. YimiumTimi^^
aulilii.m
mn
1 fl Iflafi propranolol
thioridazine,
thioridazine
nu
nu
^aTUL/i^iin-sijj mfluun'uvian'ua^flms
fluoxetine,
carbamazepine
nu
n"3'3ajni-3'5:;iJii!jnyi'inT3pfn!*niIfiJvn
fluoxetine,
carbamazepine
nu
niiiii
tciuapiaitflii'uIuuiEJ m-atfliuuismuu
macrohde antibiotics, phenobarbital
Llguli tteitfi-ac^'uuel'U'um^^
nu
nnilviFnnul \xmm
flowchart
^iini^
iiium
3. m^sjd'JuiQU'ua^wJj^T-u
tnyTua-^vinfJiny M a n
wa°niTEjnii
a^fl'n-savivijj Rfusn'sijjnni'asjuuun
mime^
U]^^!
m m
propranolol, phenobarbital
nu
valproic acid aas; phenobarbital
nu
carbamazepine
3. wdsQumuQ'aa^alfliQiifTunnvi'Ufl
aiJQVin^ni-silguflvi'aflwulunn'ad^flaiiaija
lwm^iinimaflni,ui!nni ^^fiiiavien'ijnyi
nan
lumi^flioi Focus group
me\iv
fuwfl'Baui.la-^m'a^flmiannn'sljin^
il-atei^fl'^nnnniHun ^silisnauflQuaviviu
iiun'uI'uiJ'asi.lufln^n
TfluSnaaj-^nu
m^'Bniijji.fl'una^ni^nFrfyl'U'f'Ufla'Ufl'i^an
tfi^'Bnii
vjununa aa^ijflanniia'u^
mnuQ'S'a^
4. tdafiniiinu^n'umaa'im'aa^^u
1. mi^pipr^flfu:;nmjnn'3isui]un
tfianajunisuuEjn'ija-^einniT'u
I. S n Ii s 1^ a n n n
niif^am-j
na'jj-anumgf'Bn'aiiii'sjsi.fluw'Bnil'asi'lfl
knuiiaija
mi
aatCiiimjmiiJisLduflnijauu
ii fi ^ ll-a s 6^(=1 ^ n n n n *aH u n ll-511 d uflT n iiii n ^ s L ll u u a a n n n i l 3J fl ^
f^fl-aaupiaajfi^a m-aawn un^niiit^ij-^^^
il-ats^^fl'nuun tia^ Naranjo
5. Ifluuvinilis'Tflfii.fiuTii'a-^nu
aasaufl-anluTatviQn^aijn
2. FifUsn-a-aum-aitDUun IflnnviUfl
anm-jliimil'a sa^fl'^nnm-aHuna4ii av^ JJ
Journal of Srithanya Hospital
46
iJ'ssiflua-awiJiEJi.tasi.^axjIu^mj'S'ajjaua^
c^mLTu
hm^
sfnvifuiJflann'amiLtnnuyi
Xmmini
vin^anniLmviijaatVi'uiQU^n'uyii^FiaQfiviri
muQ'ua^
i s f l u M m l ^ aasiJ'aS'BJjmaisfljJi.tafl^
6. <fl'Mn'3:;uuni'3i>fla'uanfn'3liJw^
mittnun
n-fajjianamJ-asnaiJ
uas/vila
pnnajfifli'W'u'liiiisiiJUUiJgupi flowchart
il'ssffuflnun^Fi
Hfnl^iTPi
Doctor's order sheet ttasiiTu^nm-s
iiasviiaunu-^nji.Slamflanfnii
lane^n'avian^n'ui.Lasa'uija'U'Upin-^'] (pnm-^
u-avniunDawuiina
yi 1)
7. ^flni'sau'Suui'su'iuQ'ainn's 5
f\i<\a Lia^mitmui Fnn3Ji=iaifltnaa'u
aLrfimifrlaun^flai,tia^a3jnta3ja
yn^EJT F m u f t l a ^ i n Abihfy EJifnan
Iif=i^PiQni.Q"u uastla^aimiliiwiJisa^fl
8. Sm'a^flmu'Liaija i,i,a""3nu^TU
ma
Wpuun-anuLfln'a^'Ka'in'iil.iiwiJ'iSsi-^fl^nn
nTaHEjn^munflQiiit^u^a^ttasuTfnyn
q
qj
lann^vi 1 iananiiLas;^^auLiG5uu»La^isLJi)i.Hii"Q^annn'5lji'w^^
i.anan^aasi^agsiJijaTJtiiia^'asiJiJi.plnisT'-^annn^ljiwiJisa^R
-
istiJuiJiJgiJlinnififlfliiianni'aliiwil's:;^^^
-
ismuiJiJgiJlinni^flnn-sunyiLfiflaiiflifilunitvidn^m
- Flow chart nniiflii.amaM'wmflnnitmun,
m u i i i
- Flow chart ni'sflaawiJQjjfil.'BEnfiSFnnsJi^u^a^ aas; unffiwiT-jFi^Pi
- Flow chart
-
(uiiimm)
nii^miwimnrnmimiiiizmi^iii
imiJa'siJfiflflniiannniljJwiJtsa^fl/annnii.mun ^inmiH?jni,tfi"fnififlpnjjunyi
ai^tfiflaufliniunisi'iQn^uni.i.asnniflflflniJFiQnjjflaifli.flaaur^
-
tmuiJ'ati.d'UfniHunFnnsjt^Ej^^^ (amiT'un'BTuns))
-
uiJijfiflflniiannnil,jJwilij;a^m'innniH?jnffiwnIifl^fl (afnLrun'B'i'una)
-
tmunu^ntiaijlim'aiu / m'3Fi''uvnFnnjj Ju-^
q
-
tmiJiJittduflinaJiJn^siLfluiJa^annniliimiJiSe^^flniJU'iija'^ Naranjo
-
i,an6^ni=nn3j|i,1a^ aifniljimiJisa^fl ' u a ^ m p n i i i JEJ^a^3i,i,asunfn»'iI'5Fi^fl
-
(?l1^u^^EJ1yimflal!fl1in1u^'5:;vi^^^3iJ^
Qn?«^n?t?'3viynuna^ffinjfij'i i l ^ 11 •aiTiJ^ 1 iini-iflu 2554
" " 47
mj^nuitiwilQuI'uiitvid'i^an'i'aniJuii'i (Lflau
nsj/nmjs 2552 mtfia'uri'uunu'u
TflEJvii pre-test LiJIuumtiUfTu post-test
2552)
uasvia'^nTanajui'ssuii (tflauflaiflsj
2552 fl^tflaudtnflJJ 2553) fla 2,758
uiinu-iI'Sfl^fl ttfi will ulvidmu unrmwi iias
uifnyil-afl^flvin-sn?]
iie^z 2,983 iiii fliiianflu
lu^nuiuu TAiu-jnyxg-TunTai.nflanm'a
flflfliuanmiiliin^a
iJ 1 55 ^fl'^n n m i H u n u a >a w ll T u fi d m i H Idwilisja^fl'^nnm-aHun^nnunflniiL^u-^
!jn flinaj u^ aasuifnyiT-sfl^fllflfau a s
a-^uasunffimTifl^flfiau isivin^ iiasvia'a
100.00 dmiflflflnjjainTjliJmiJiita^fl'
nniiwiin'3s;iiii
^mmiHuifl'ai.ua^^nvifuwil'Jumflutfifl
n u flflLiluiauas; 0.24, 0.80 aas; 0.50
annTaliin-^Llisa^fl'^nnnniHuiisflu
lia^^nuiuflf^iia^ann'aHmnn'swviiiflflnij
Milyin-jiu
uas;dmia^fln^
5
CYP 2D6
•^luiu
7, 22, uat 15
anflii
iiatCYP 2C19 tuinufjdilnjvn a^awam-a
2.2 m i L i i n f u f n i f n y n i . u a ^ ^ n n
fln^IutTa-ssmu'uf^iJQuI'um'jiJfuD'uifl m fl a n n n nld
ll "3 s s-afl'^n n n nnH u 1
unlfl dmii.e^i'aS'T-^anm'sldwilisa^fl'^nn
fln3Ji,^u^aa-^Li,aj;uT3nii'Tl"3fl^fl wiliumfifl
rniHumf^ tf^-snlflun ajj^Tu t/i ^•aniiii
aini'sIiJwil'j-ei^fl'-^nnm'jHu'i
uatfl^fu^iniinu^anuain-TsldmiJisei^afl'
mnnliili^nunina luiJQ-aria'unninaiin
^nnnniHun dmiiin drug profile ua-^
-5^1111 d^ntnu 1 n u •^nnnu-^Tum-si.fifl
^ufla-^fu
anm^ld'^-^il'atsi'afl'^nnnn'aHui mwiifl
7 n u I'U'stvin^m'anajui'asiiu dwiliu
fJTUvi 2. wamiil-3ti.duLlis;^viBwa
lumfiinnifnwnl'uLi^viuiii'iaa'uma^^nn
isiiJijnTsi.flTisi'T^ann'i'sliifl^aiJ'ssci^fl'^'in
i fifla 1 n m l d n ^a iJ 1 s 55fl'n n n n 1 H u n
fiTaHunflTiu t^u^a^ LiasuifmHTl'Sfl^flTflu
wiiiiu
iiJlEJUtviEJUiiaijaria'u
Idwilisiei^n'-^nnm'aHun miu 22 nu)
I S V I Q I ^
uasvia-^
1 n u (^nn^TUTumfiflannn-a
u fl vi a ^ ^ 1 nl fl u 11
2.1 ^ T U T u n u ^ T u n T a m f l a n m i
laJwLJise^^fl'^mnnHEJifliiiit^u^a^n.as
s 1111
^ I T P U u n ll, a Q jj
nH
n a u l d w 11 w ll T u i.'yn n n l u T i ^a n u n u n a
autua^^nnmflaim-aldwilita^afl'^inm-s
qj
uiihid-Tlifl^fliia^aainiT'U'sn'Bn'un a
^ 1 n ^ n u Tu w ll Q u II a ^ a fl n iTul u ij 1 >^
riaum'anaj'U'i'jsiiu Ifluri ^JT^tflau
unnflu
2551 n-^3jnnflij 2552 f ^ d
ui}imiiii'umiv.
HuTLau
(^nn^'nuTumfiflaimiildn^
ilisa^n''^nnmiHui miu 15 nu)
2.3 fn1mflanfn1ldwll'3sa^afl'q^fl
m'5HuiflQn3Ji,^u^65^n,as;u'ifnii''il'3fl^fl'Sn
2,915 n u ^^natflu^
Journal of Srithanya Hospital
48
^ 1 n "ua il a n T3 tnfla n m ilii w LI Ii t a-a fl tiu^s^-^uasuifntnTifl^fl ^TUTu
^nnm-sHun riau isvidn-^ uas^via-^mi
najin-ssuu ^-^fi^iuiu
nuflnuanflU'U'u
7, 22, uas; 15
viumitnflainT3l,iim
7 flf^
a a " kfl "u a n m i l i i n i J 11 a ^fl'^1 n m i H u n
Wsflu
^TUQU
6 flfa uansflii 6
5 ^luiu
1 flfa
6 flf-a
lu'umtfiiJi^i:;'Mn^3nninaj'unitiJij
lu'jJi^fia'Ufninaj'UTstuu ^^iflu^fleiTU
tnfla 1 m i l i i n ^3 LI 1 s a ^fl'^1 n n 1 i H u n
fi^^fisifl
flQiiiL^u^a^LtasEJifnanlifl^fl
ili^a^fl'^nnmil'BU'TSn
LAWTUQU
LSatfiuijnu'iJT-ai^vi'Jn^uai;
MS'^nn-jviiaiuiisiuu
^lAiumimflanmii
liiwiJisa^fl'^mmiHuTSiLflu^'anutflUQ
^lUTU
22 flf^ ^sifluanmiliiwiJiss^fl'^nnmi
HEJI
luisflu
4 ^nuQU 9 n u
iiiu
anniiliimili-ei^fl'^nnnniHunl'uisflij 5
1 ij n >a iJ-3 s §5 ^fl'^n n m
•a EJi
1 vi a ^ n m
^nuiu
12 n u
Lta:; annmliiwiJisja^fl'
^nnmiHui luitflu 6 iiuiu
1 nu
2.4 isiflUflQisjiuai^ua^niiLnfl
uatl'uiiQ^via-^nniiniJU'uii^iJiJ n u n
amiilu'wiJisei^fl'^nnmiHu'iflTiuiaEJ^ei^
mflanmiliiwiJisa^fl'^nnuiflQniJi.^u^e^^a
ikasEJifny-ilifl^fl
i,ifis;unfn»'iliifl^fl
kSan^iimnf^itflUflnu'j'uii.i^'iia^a
m 1L nfla 1 m l l ii n ^3 LI 11
nun
G5 ^fl'q1
nm l l u n
fiiiij;flUfl']nii'5'Ui,ml'U'3Sflii 3
tias 4 niifTUii^n'UTu 20 fli^ { i m e \
45.45
wviiifl) iifl^n'UTua'innliin^iJisa^fl''S)nn
uat
3 Aiiiiu
IUISAU
1 n u aimiliin^^iJisa-afl'
^nnmiHui luisflii 4
-^IUTU
10 n u
ainniliiwiJiSei^fl'^nnnniHun
luisflu
5
ua-^aim'aliiwiJ'3"a^fl''S)nnmiiH!Ji
niiHun
15 fln tflu
ainiiliiwLlisa^fl'snnmiHun
^in^iUTuanmililn^iJi::;65-^fl'^in
miHin
^nuTU
<nuTU
4 nu
Liadiinuannnii
liiwiJisia^fl'^inmiHui luis;flu 6 tau
(FNflm^vl 2
^iiisflUflTijJi'ui.ml'Uitflu 5
tSan^nianiiUfliia'^unaatanmii
6 niiriuii^Tuiu 24 flia (lauas
mfifl anmildn^3iJi:;a-afl'^nnm'5Hu'i'a''n
54.55 '2ja^a-imiiliin^iJis;a^fl'^nnmi
nun
I'BUTin^vijjfl) ufltiiaLiJIuumuumimfl
annniliJwiJij;a^fl'qnnmiHui^i
a n m ilii n^ LI 1 s 65 ^fl'^1 n n 1 i H u nlu 1 sflu
6 fll'^ Lfifl^nn haloperidol
flniiiuui^fli-a^
thioridazine
2 flf^ (kfifl
tardive
dyskinesia
uat
kfifl^in
risperidone
1flf-^(kfifl
lu
3 liQ^ua^miPfnwn
nun
lOTQ^anaunniinHJinis;!!!! flnu^aiu
mitfiflanfniliiwiJisia-^fl' qnnuiflniii
luiiQ^naunninkj'uiisuu
dyskinesia) clozapine
nj?5n?t?>3ntnun«?i1finjajn I\Y\1 'aiTu^ 1wnn^iii2554
" 49
EPS)
dmitnfl
miu
iQiJnu
tardive
1 flf^ (mfl
tardive dyskinesia) tfifl^nn risperidone
thioridazine
iiam
mz
1 flf^ (mfl EPS)
thioridazine 1 nf-^ (mfl EPS) tifl
lu'ilQ^-aS'W'ii-anni'Maj'U'i tfiflanmiliJn^
WTsn>afi 2
iJ-3 s a ^fl'nn m
i H u T ^ n m u ^flf^ I.flu T=5 n n
risperidone 1 flfa (mfl EPS) aatldviD
m
1
tnfla 1 m l i d n ^ L I *3 s a ^fl'^1 n m i H u n
l^ntauliJiJQ^vi^Nfi'iimj'un fl-aflnii^^fi 3
i.iJ1uijmuijnnimflannnildwiJita^fl'^nnnniHunfliiiii.^u-^^^aatunf^
liflSfliia-awiJQU'uan riau iswn^ i.tai;via>anni'imj'uni"iJiJ
iNaiun^suiJ
2,915
2,758
2,983
7
22
15
0.24
0.80
0.50
1
1
0
6
1
0
- ISflU 3
0
0
1
- XflU 4
0
9
10
- itflU 5
6
12
4
- ISflU 6
1
1
0
7
22
15
iimiuniimminiiliimii'it.^m
- iiuiu
(fll^)
- lauasna^^i'UQUwLlQLifil'amnn
fnii.ii'ifunn'afnwn ma^^nnnmmfl
aimildfJ^iJ'asgi^afl'^nnmiHun
- ^TUTU (flfa)
nniLfiflannnildwiJiitei^fl'^nnnn'jHu'i'Si
- ^nuQU (flia)
isflUflTiiii'UUi^Da^miLnflanfni
IdwiliSei^fl'^inm'aHun (flf-a)
wafnikHnitQ-^m-amfl auflinlun
isuuLQau
8
nuflai.fla'uuflldnu
•jsviQ'i^unnijQndrniiHflLin^an^Lfifl
amnildwilisisi^fl'^nfim'sHLn
aufliniunsiviQi-^un itvn'n^auasiVia'^npiJU'i
auflinlunisMQi^un
Journal of Srithanya Hospital
50
tda^a^in
Aunfinufifl^u
phenobarbital nu sodium valproate 60
•Liaiifimiiflflflnuannn'alsJfJ^il'SSei^fl'^nn
ina, phenobarbital nu
niil^iiiii^il^iiiiinimiiim'iiijmm
carbamazepine
5 iiii, thioridazine nu propranolol 1
liii,
nu propranolol 1
phenobarbital
inu,
phenobarbital
valproate
iQiinu
nu
drug
lunau^nu
profile
m^'Bn'aisjuhafl^viinui.QvinsI'unau^TU
am
sodium
L/i^iininldanijnifi m u i i a i j alu rais m uu
nu
aflvia-^^nnMPUuniisuunn'3i.f^n'5s;'!Nannn"5
phenobarbital
carbamazepine 3 liii
Ifl nnitnu
phenobarbital nu
liin^ilita-^fl'^nnnn-aHun
nan^nu
sodium valproate "SQunu phenobarbital
m^nn'a'aiilfl'unjTU'S'aija
nupropranolol 4 mu
^asnilMnuvijjavia'iunTiJ'i^vi
drug
profile
dnni
inu^n'U'iiaijaflQniJflanfltflaa'uvin^unl'uvi
ilis'aua^fl'niitvivigjvini.flat! ttatuu^n
1 . m^'waj'UTjsiJiJfntiplTSST'^
a n n 1 "sl jj f i ^ l l 1 £ n >a Fl ^ n n m
y 1 FiQi i j
'3'aiiaannn'3ljJwiJ'3sa^fl''S)nnnniHun'5tflii
5 ^uliJMiJian'aiiwiJQU'uan i,i,ai;i,i,uu
u u^nfl11 u Li u^ V11fl I unlu t T H i i u u u
Fiaisniiunn-avinwunisuuiJitnau
^ ^3 ?i n il n 1 fl i a sniHrTu vi 3J 65 vi cin in 1 n ^ VI
VI-5 n u I, vj a 1Q il ii a n u il a ^ n u a 1 n 1 l l ll vl ^
tmyiu
nununa
t^^'Bni i a i -^mi
ismuuiJgulipin^n
iliS65>3n'^nnnniHunvianijnini]a^n'ulfl
^^ii.^'U'i'i m-aaanttuuituu^-^fla^
i^muuiJgufl
if^nisT-^aasiLla^n'Uflinjjna'iPii.flia'uvi'i'a
fflfiiiaastviijnraiinuuflann'aija^afinu'u
un nni^flnniunfli.nfla'Uflinlun'atvi'in^^un
Tflulil 1,2 u/n 1 t l VI n u m vi un ^ i n n m ulil
nTa^PinniunFnniiL^'u^a^ nnifiiFipnii
uattiiaiiminiitflu lont'Wfl'ui.flULS'u^n'u
q
anmiliin-^LJisei^R^nnmiHun m-jula^afTu
neiniiniifiil^ufllfliinn^ij'U'umfl^nn
liizii
nnitmui'Bn
itasfiflgiiiiwa^nnmiiiJ^uli
flnuis;i.uuuiJ3Ufl unwaffliliiiiQi.flini;^
nn'ae^'uue^ij'umn-atfluiiluu'iu
mflkfluituu
vi u u a ^fl-31jj ll a afl/iutu n T a H u n 11 a ^
Immiuiu
m'Se^mu'U'aiiJi'una viii^Tuviraiira^ an
iJ fu ll-5-5 itnlii i] fu V11 vil a 1 s tu u u iJ 2 u ^t'w
mnntnueifnuim'anuna
q
q
V
Iflim naii-aTut/iauniiiJ
mSuunuvian
uatnn'aiieiQijniiija^awSfiQ'umsjQiia^vin
IflUfi wanmunni a^fl'niimviu
eifinu'U'ai'anuna
kfljjninnn^n'uniiClantiisvtQn^viii
flfutn-j-siinniituuEjn
nan
tmvisj nununa
eJaflflaa^nu-snu^numn^u
aviQinfnttimiflflflnjjanmiliJmiJisisi^fl'
{^^mi
^nnmiHunU'^ljJi.ii'uiils'aiii tua^aqnn
iia'^nfj^n'uua^TuiinuatflaitviviUQn
-51 u u n 1 "51,T31ii^ n m tfiflan m-alii w^
Qn?fn?t?>3viinun?5?i1finjnjn i l ^ 11 -auiivi 1 iinfiflii 2554
" " 51
u a 11, nu t Q-^ m 11 fifla n n n "alii n L I "5165 ^ fl'
fum'36^uu6^'uu^inwu^vn'3 m'aii^at'ul'u
^nnm'sHuninn^'u
ni'snRj'unflfu/invN'iia-^naiJL/i^'Bn'j'aw
npumituudinu-^nu^nuQunniififlainni
uat
•nnH^iuvia^nm
Id w i l i t a ^ f l ' ^ n n m i H t n aflilaEi a-3
a n LI 11Lflu vi u ^ ^ Qfl ll-311 n 5 w a u a ^a
cnjjufiflU'wuanmiliimiJ'ata^^H^nnfni
H u i M m u f u ttatiiiEjafllamaviwLliumfl
ituulflim
nTsmfum-sfnmi.da^^in
qj
m-3 mfla 1 m l l d m iJ 1165 ^3fl'^n n n i i H u n
miiJisi.lj'uisiJumii.S'iisQ^
2.
aatnniLfiflannn'sldmil'ata^fl'^nnmiiH
a n n n 111 ij vi >q iJ 1 a ^ R ^ n fi n n-aH y n F) Q1JJ
mil
i3 y ^3 a>3 Lia s; y n-fnMnl'a Fi^ PI
n'3f^'3tvi'ii^aat'wa^nmvrpu'UT3tuu
^nninu^nunuii riaunn-aTArpuun
ituu
dnu^i'um'jLnpi
iJitsi^aFi^nnmiHui mm
0.24)
annmliin^
1 Fif-a (fauat
iiatmajf-uiiJuiauat
0.80
Xmi^
f^nuQT iJiJjiaim'si.nfl'ija^afNSa^a
diliJjnaiafl'uaua-an'j'ina'unninpuinituu
Iflaui-a'BflW'u ^nn-fauat
ua^
14.29
nu^a Turn's Lfifl an nnnldn^ilita^fl'^nn
nniHui
mnflnauminpij'un'stuu
uat
•st'WQi-aminaj'U'liituu aaQaPia^waaiatJ
afla-^kviaa-fauat 4.55
at
0. 00 Ma-aniiiATpuuTstuui.LaQ wlannimfl
0.50
lu'BQ^via^n'i'svrpij'umtuu
ImtviQi-^tLat
a a PI Fl a a nu "a 1 u ^31 u D a ^a 1 u u n u a t Fl fu t anmnldwil'Stei^afl'^nnmiHun'Snua^nau
vinudi ^nuimnu^iuanm'aldwiJ'atsi^Fi
itvn'n^
snnmiHun
^nn
ria'ULiatvia-^nniinpu'uniituu
FiPiLfluiauat 0.13 aat 0.52 ua^^nuTU
uatvia^nn'snpij'unituufiafla^
6 flf-^ L S U 1 ?\HA itatldnufliii
anflu
u a n ^ n n d l ufln u-31fluflQ n 3J-5 u u-3 ^
Fil^iia^nniHulni-awviiiPiPinjjanpru'' ttpi
q
wa^innu^TuS'iAiu^n'UTunnimpiainn'3
na^nniLfiflannniildn^iliita^fl'^nnnni
Id n-a LI 1165 ^fl^ n n n n i H tl n tfi 3J f'ulu li 1 ^
H u nTO'stfluflQiiiiuLL's^'U'stflu5
itvi-in^minpuunituu
6 iia^'BQ^na'U i f w J n ^
f^aa-^niniJQ^ria'u
minpuLnituufi-^mau^mn
uat
LtafMa-anpuun
uatpiaajnafl
ituu'^nn 7 fln LvJajTOLflu 13 flf-a uat
a^ m a a m aufll^M u^luii 1 ^ w am-3 n pu un
afla-awaa 4 flf-^flnjjanflii uatlu^nuTU
ituutflumluu-fauLLaT
dldviuannniildn^ai]'3ta^3fl'^nnnn'3Hun
•M-^umntl'uiiQ^aitvidn^ann'anpu'U'i
luitflu 6 i.aunnu'wa-anninpU'unituuu.aT
ituudni'SfliitviiJnija^wdai'ULfiuQ'Lia^mii
jjinfu
i >31. M a 1 u a Q u u 65fl^ n ^ n m
VTPU u n
^-anunnii.nflannnildmiJ'ata^fl'
nfu/inn-^n'uu1m'3yifl!i^^i!ua>a'3tuunni[
^nnniiHtnaatnu^nui.Llu^'i'UTUuin^'u
1. p l i ' a t i N a n n i i l d m i l i t e l ^ f l ' ^ n n n n i H u n
q
Journal of Srithanya Hospital
52
niiiTputnisuLinniLSni^iNanmilji
annTslsJ^^Llisei^Fi^nnfniiHyn
^3 LI-5" el ^ R ^ n n n n-3 H
mitfiPi
aini'aljJ'M^ili^ei^R^nnmiHyn'Sn
y n "jj a ^3 el f i n l i t !
"ai'snunei^nLf^pi'QyLl^^yanFrfu
usis;
If Hi
n n 11, n PI a 1 n n 111, l i f l ^ i l 1
I'U'jspmi'ui.m
il 1
i n 3/11
piFi ^nnnni H y 1
\mf\
LiiunniiUciPi^QTSsuulvisJS
H L VI
3 PITU
^
m
^nU^LTOuf^
UelSni'aCie^TuiQW'Lia-^WViS
n ^ el II n u u 1 u VIII el
UFiGinniiia-^eifniT'u
n.6i"Uf=ianniCi(=ni3J
I
11 ^ a n m i l l i m
iJ-3 s el ^ Fi ^ 1 n n
EJ n f i
P i i s ' M ' u n p ^ u V11J1V1 tteisClFmu m M u n n i
wijn^ieiajmjatiniJmn'anunaviflapiinrin-sH
iJ 2 U Pi PI 13^ 1 - LI IJ Vi VI n Fl U S ei T U - 3 1 3 J P U 1 1 n
y 1 n u'S'ri tt " y n 1 n m i l Fi ^ PI ^ S til u y n n el 3J
"u a n^n n i f l u m 1 Pi PI 51 n 3J F n n 3J G1 3JU i f i l
n
y n u n n i l L n PI a n n n i i l
'ua^iJu^nasisiny^anuannniiliimiJ's^iei^Fi
nufHynl'Msi^TO
^ n n n n H y n
I
^ n n m i s l j j p i i Q ^ a a u m i
I^ y
lAi-fajjmeiPim-smvrn
n u 1 el I, u a ^ ^ n n L fi PI a 1 m i l a J ^
iJi:;6l-^R'^inmiiH£jn
iTu^nannniliJwiJiSei^R^nnnniiHynfnwn
1 aJ w iJ-3 ^ el ^ R ^ 1 n m
m i l
mf[immzmPi\.iim
SuiFiii
2552
labels
61.00 a e i s f i i . m u i J u ^ f m p i l j J f l n i ' j
imfin
1
Im
itimz
39.00
Uei^i-^nnmi^nTsj
PTU F i i 13J m VI al^s) "ti a ^ w LI 2 i J p i PI n 3J1
20 iimiiii
iimumiii
Fnnii w v i a H u i s m L J U L l ^ L i l i v i n - a i y
adn^alinpim
y n l li-3PTD 1 u L11 ^
neimn'a'aiJtJ'asmFi
iia'ijauRaian^iiiy'nfpiu
MpniJInwn
vinvinu
yia^iapivi
R f u u u e n u'B^ii^viii.'US'U'ifn'a
t^EJUwei^Tun^D
Fni^puuiis;uijmi
ueisinnimpianni'S
I m a y a'^n'i1ria'un'l'^'^^^p^J"U'^a yn^'S'pi
uu
wiJgijpifi
fJ ^ LI 1 s e l R ^ 1 n
iteisviajGivianini'ai^w
mwunvivitfiyQ'^a-^mjnni'i^PiJ'Ui
I, n 1 s Q a 1 n n "alaJ •^^ LI 1 :i el ^ Fi ^ n f i n n i H u 1
'asiuu^nL'unnLviRQnsjnusjaviPU'uiisiJU
H C i Fi ai/I n
m-31
pi 5 T O a ! i 1 ^ pi a m a ^ el 3J1L el 3J a
PiT^m'jGi'uuei'uwinii^pfu'uTyLny
q
•^TUtfl^'Bniiii
T 3 Si-T^ a n m i l jj m LI n el ^ R'^ 1 n m 1
n^n
s
n.ei^wflsiQ"umyTi)a^
mii
I.vi a iJ 1 :i ff-u Fn 13J i l si a P I / f y l u n n i H y n PIQ
' y
n n-3 L n PI a 1 n n i l 3 J ^ LI-5 el ^ Fi ^ n n n n - a H !j 1
Ua^J^elP)
Qi?2n?T?-3vi!inun9^ffiqjfijn t l ^ 11 -amj^ 1 wn?nfi3J 2554
" 53
Fn'ijJiJ§ia«^raa>3wil-gfj.
2548.
mmii'sziii'smim;
fu Tuvi
3 1 minii
2550
-
3 1 y<fiwfn(=ijj
6.
2551.
2.
^mum m^M-^i.
1. ^ j j w f i l ^ v i
Prevention
2. ni^Jii.vi'HjJvnuFii ; m w i u ' j l v i E j f J i i i i n i t w j j ' w
Taxonomy
; 2540.
3.
Ferrell
PB, Mcleod
HLA-B*1502
Johnson
of
Stevens-
and toxic
epidermal
: US FDA
Pharmacogenomics
Error
Council
Reporting
(NCC MERP).
:
m i 3-7
Coordinating
for
and
The N C C MERP
of M e d i c a t i o n Errors 1998. [online].
Available from
Carbamazepine,
a n d risk
syndrome
necrolysis
HL.
National
Medication
mH'Sim'M.m
n-j^mvijjvnuR'j
: http.//wv\?w.
nccmerp.org
/ p d f / t a x o [ 2 0 0 1 J u l 31].
recommedations.
2008;
ljj'miJ-5:;a^fl^nnnniiHyi
9(10):
iJi^^nfl
2550.
1543-6.
4.
flujjfiifi^njjanfn'aa'ulii'w^iJ^ss-^fi^'in
mil'BwSw/i'ai's^'a'jjflnn
n^t;vin>5pnB'i'3fua'iJ.
Spontaneous
of
report
adverse
2552.
8.
drug
aEiJ*Ba
reactions 1998-1999. wuwfii-^vi 1. ni^mwsjvntifii:
^ J4 u 3J gi M n-3 n j n 1-31 n » 1
s«i
u-^anuuvi,
3Juvifw3J
T\iiz^<f\mwu,
dnL/nwu,
m-iiii
anEJ'BEj'B'iaj,
& i i m
u. vi >a LI n s m fll VIEJ;
ififiiajj,
TSJJUEI
nu»2i
mynn-sns),
'wusFiluiwgi.
nn^'wwun^tiJiji,Hn^:;T'^nn^in^a'in'iiljim
2545.
5.
-iuni
m m liizmsiwuz,
nnit^laivifviEj.
wan-s:;!/!!)
9.
•^Ja^^fn'l3Jfl^)•1Wl.nsaunn^tJ1siatt;uun•^^^l,l,5^
Tl^nmuna
2550:
17: 4 7 - 57.
a^Q-j-sa!
PlaiJn^.
nn^i^Jn-j^-T'^/ims
l5J'W-3iJt^5(-5R^')nnnHun:iJ'3t;aum'3fu
wiQwuvia, LII'B'I Jjuyimufins u-jituiBmii.
Ti-srjDiing^filBfijfy'i.
nuila-antJHTiUfla'i^tHaauyin^unma
im-^Ll-j^mfllyiy
Journal of Srithanya Hospital
54
inigfu^iDni'w^^
2 5 5 1 ; 15: 33-47.